Jul 13, 2022 / 01:00PM GMT
Operator
So I hear we are good to go. Good morning, good afternoon, and good evening to everyone. Thank you for joining Sanofi's Hemophilia Investor Event either here in London or online. As always, the slides can be found on sanofi.com.
If we could go to the next one and the next one, please. Yes. So as always, I would like to remind you that information presented here contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.
So next slide, please. So for today, we've put together around [2-hours] event to show Sanofi's commitment and ambition to improve people's lives living with hemophilia or other rare blood diseases. I mean you're going to see that there is a broader portfolio that we're building here. And in the context of ISTH that has just concluded, we want to focus today on fitusiran and efanesoctocog alfa. We're very privileged to be joined
Sanofi SA Hemophilia Investor Event Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers